|1.||Fan, Yue-Zu: 10 articles (02/2015 - 11/2004)|
|2.||Kuo, Cheng-Deng: 8 articles (06/2015 - 03/2005)|
|3.||Chen, Yu-Jen: 8 articles (06/2015 - 03/2005)|
|4.||Liao, Hui-Fen: 8 articles (06/2015 - 03/2005)|
|5.||Sun, Wei: 7 articles (02/2015 - 03/2006)|
|6.||Zhang, Jing-Tao: 5 articles (02/2015 - 05/2012)|
|7.||Liu, Zhong-Yan: 5 articles (02/2015 - 11/2012)|
|8.||Zhao, Ze-Ming: 5 articles (01/2014 - 11/2004)|
|9.||Li, Ying: 5 articles (01/2013 - 01/2008)|
|10.||Li, Jun: 5 articles (01/2013 - 01/2008)|
04/01/2010 - "These in vitro results suggest that norcantharidin may be a safe and effective anti-cancer drug for CRC."
06/01/2014 - "Synthesis and antiproliferative assay of norcantharidin derivatives in cancer cells."
05/01/2013 - "Norcantharidin inhibits tumor angiogenesis via blocking VEGFR2/MEK/ERK signaling pathways."
12/01/2011 - "Norcantharidin (NCTD) has been reported to induce tumor cell apoptosis. "
08/01/2010 - "To explore the inhibitory effect of norcantharidin (NCTD) on the expression of DNA replication initiation protein Cdc6 in cancer cells. "
01/01/2013 - "Norcantharidin (NCTD) is a promising agent for inhibiting renal interstitial fibrosis. "
01/01/2013 - "Norcantharidin inhibits renal interstitial fibrosis by blocking the tubular epithelial-mesenchymal transition."
02/01/2012 - "Norcantharidin, a protective therapeutic agent in renal tubulointerstitial fibrosis."
12/01/2011 - "Norcantharidin (NCTD) was shown in our previous studies to attenuate renal tubulointerstitial fibrosis in rat models with diabetic nephropathy (DN). "
01/01/2011 - "Norcantharidin attenuates tubulointerstitial fibrosis in rat models with diabetic nephropathy."
|3.||Pancreatic Neoplasms (Pancreatic Cancer)
11/01/2015 - "Therefore, in the present study, we investigated whether cantharidin and its derivant, norcantharidin, could repress the stemness of pancreatic cancer cells through repression on β-catenin pathway. "
11/01/2015 - "In conclusion, we presently propose that cantharidin and norcantharidin hold their promise in pancreatic cancer therapy through repression on stemness and strengthening the cytotoxicity of the present therapeutics. "
11/01/2015 - "Pretreatment with the β-catenin pathway inhibitor FH535, attenuated the cantharidin- and norcantharidin-inducrd repression on CD44, CD24, and EPCAM, suggesting cantharidin and its derivant repressed stemness of pancreatic cancer cells in β-catenin pathway-dependent manner. "
11/01/2015 - "Furthermore, cantharidin and norcantharidin strengthened the cytotoxicity of gemcitabine and erlotinib, two well established pharmacotherapeutics against pancreatic cancers, indicating cantharidin and norcantharidin could be promising candidates for reversing drug resistance in pancreatic cancers. "
11/01/2015 - "Cantharidin and norcantharidin impair stemness of pancreatic cancer cells by repressing the β-catenin pathway and strengthen the cytotoxicity of gemcitabine and erlotinib."
02/13/2009 - "To evaluate potential agents of therapeutic value in tissue inflammation, we studied norcantharidin (NCTD) and its derivatives for their effects on immune responses of human peripheral blood mononuclear cells (PBMC) in vitro. "
01/01/2008 - "Norcantharidin ameliorates proteinuria, associated tubulointerstitial inflammation and fibrosis in protein overload nephropathy."
|2.||alginic acid (sodium alginate)
|3.||polylactic acid-polyglycolic acid copolymer (PLGA)
|8.||Epidermal Growth Factor Receptor (EGF Receptor)
|3.||Chinese Traditional Medicine (Traditional Chinese Medicine)
|4.||Heterologous Transplantation (Xenotransplantation)